Bionano Genomics, Inc. (NASDAQ:BNGO) will release earnings results for its fourth quarter, after the closing bell on Monday, March 23.

Analysts expect the San Diego, California-based company to report a quarterly loss at $1.40 per share on revenue of $7.85 million, according to data from Benzinga Pro.

On Jan. 12, Bionano Genomics said it expects fourth-quarter revenue of $7.8 million-$8.0 million and FY25 total revenue of $28.4 million-$28.6 million.

Bionano Genomics shares closed at $1.12 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • HC Wainwright & Co. analyst Yi Chen maintained a Buy rating and cut the price target from $11 to $7 on Nov. 24, 2025. This analyst has an accuracy rate of 65%.
  • Maxim Group analyst Jason McCarthy upgraded the stock from Hold to Buy with a price target of $8 on May 20, 2025. This analyst has an accuracy rate of 44%.
  • Scotiabank analyst Sung Ji Nam maintained a Sector Perform rating and boosted the price target from $1 to $4 on April 2, 2025. This analyst has an accuracy rate of 57%.

Considering buying BNGO stock? Here’s what analysts think:

Photo via Shutterstock